MedTrace Logo

Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19

NCT05305456 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2022-12-06

No results posted yet for this study

Summary

This study was conducted in a randomized, double-blind, placebo-controlled, multicenter clinical trial design. Two groups were designed, the experimental group and the placebo control group. Patients in both groups received basic treatment with vitamin C effervescent tablets. Tanreqing capsule was added to basic treatment in the experimental group, and placebo was added to basic treatment in the control group. The treatment course was 7 days, and the observation period was set to 7 days, with a daily visit.

Conditions

  • Novel Coronavirus Pneumonia

Interventions

DRUG

Tanreqing capsule

3 capsules per time, 3 times a day

DRUG

Tanreqing capsule simulator

3 capsules per time, 3 times a day

Sponsors & Collaborators

  • Ruijin Hospital

    collaborator OTHER

  • Jiangsu Famous Medical Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Zhao Ren, PhD · Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine (North Hospital)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-28
Primary Completion
2022-06-02
Completion
2022-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05305456 on ClinicalTrials.gov